Symbols

CCCC

C4 Therapeutics·NASDAQ

--(--)

CCCC fundamentals

CCCC Q2 2025 Earnings

C4 Therapeutics (CCCC) released its earnings on Aug 7, 2025: revenue was 6.46M (YoY -46.17%), missed estimates; EPS was -0.37 (YoY -42.31%), beat estimates.

Revenue / YoY

6.46M

-46.17%

EPS / YoY

-0.37

-42.31%

Report date

Aug 7, 2025

Earnings Call

7:00 AM on Aug 7, 2025

Meeting link.

Earnings

EPS

Revenue

Revenue & Expenses

CCCC has released its 2025 Q4 earnings report, with revenue of 11.02M, reflecting a YoY change of 112.79%, and net profit of -20.49M, showing a YoY change of 40.75%. The Sankey diagram below clearly presents CCCC's revenue sources and cost distribution.

Key Indicators

C4 Therapeutics (CCCC) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

C4 Therapeutics (CCCC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

C4 Therapeutics (CCCC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

C4 Therapeutics (CCCC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown